Compare · DXCM vs TMCI
DXCM vs TMCI
Side-by-side comparison of DexCom Inc. (DXCM) and Treace Medical Concepts Inc. (TMCI): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DXCM and TMCI operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- DXCM is the larger of the two at $29.58B, about 106.0x TMCI ($279.0M).
- Over the past year, DXCM is down 8.6% and TMCI is down 23.9% - DXCM leads by 15.2 points.
- DXCM has hit the wire 6 times in the past 4 weeks while TMCI has been quiet.
- DXCM has more recent analyst coverage (25 ratings vs 19 for TMCI).
- Company
- DexCom Inc.
- Treace Medical Concepts Inc.
- Price
- $76.65-1.74%
- $4.31-2.93%
- Market cap
- $29.58B
- $279.0M
- 1M return
- +4.76%
- +4.48%
- 1Y return
- -8.64%
- -23.85%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2005
- 2021
- News (4w)
- 6
- 0
- Recent ratings
- 25
- 19
DexCom Inc.
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom G7, a next generation G7 CGM system; and Dexcom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.
Treace Medical Concepts Inc.
Treace Medical Concepts, Inc., an orthopedic medical device company, engages in the design, manufacture, and marketing of device and/or biologic solutions for foot and ankle surgeons in the United States. It offers Lapiplasty procedure that allows podiatric surgeons to treat all three dimensions of the bunion, providing patients with a cosmetic and medical improvement. The company also provides Lapiplasty Mini-Incision precision system. In addition, it offers products to address ancillary surgical procedures, including akin osteotomies, weil osteotomies, intercuneiform stabilization, lesser tarsometatarsal joint fusions, and autograft bone harvesting, as well as for MTP fusion. Treace Medical Concepts, Inc. was incorporated in 2014 and is headquartered in Ponte Vedra Beach, Florida.
Latest DXCM
- EVP Chief Legal Compliance Off Brown Michael Jon sold $126,514 worth of shares (1,700 units at $74.42) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 104,653 units (SEC Form 4)
- Dexcom G7 15 Day Receives Health Canada Authorization: Extending Wear and Continuity for Canadian Adults Living with Diabetes
- Dexcom Schedules Second Quarter 2026 Earnings Release and Conference Call for July 30, 2026 at 4:30 p.m. Eastern Time
- Executive Chair Sayer Kevin R sold $1,926,432 worth of shares (26,756 units at $72.00) as part of a pre-agreed trading plan, decreasing direct ownership by 7% to 355,726 units (SEC Form 4)
- Dexcom Further Advances Vision of Glucose Biosensing for All
- Deutsche Bank initiated coverage on Dexcom with a new price target
- EVP Chief Legal Compliance Off Brown Michael Jon sold $128,435 worth of shares (1,700 units at $75.55) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 106,353 units (SEC Form 4)
- Director Foletta Mark G sold $296,540 worth of shares (4,000 units at $74.13) as part of a pre-agreed trading plan (SEC Form 4)
- Dexcom CONNECT Study: The Most Significant Clinical Study Demonstrating CGM Benefits for People with Type 2 Diabetes Not Using Insulin
- EVP, Chief Commercial Officer Coleman Jon sold $722,628 worth of shares (9,823 units at $73.56) as part of a pre-agreed trading plan, decreasing direct ownership by 9% to 95,450 units (SEC Form 4)
Latest TMCI
- Treace Announces First Surgical Case with the HyperPlate™ XM Dynamic Compression Locking Implant System
- Sidoti Events, LLC's June Small-Cap Virtual Conference
- Amendment: Chief Executive Officer Treace John T. bought $99,196 worth of shares (24,606 units at $4.03), increasing direct ownership by 0.34% to 7,348,439 units (SEC Form 4)
- Chief Executive Officer Treace John T. bought $210,968 worth of shares (52,317 units at $4.03), increasing direct ownership by 0.71% to 7,376,150 units (SEC Form 4)
- Treace to Present at the Sidoti Small Cap Conference
- Chief Executive Officer Treace John T. bought $177,915 worth of shares (50,000 units at $3.56), increasing direct ownership by 0.69% to 7,323,833 units (SEC Form 4)
- Chief Executive Officer Treace John T. bought $340,589 worth of shares (115,520 units at $2.95), increasing direct ownership by 2% to 7,273,833 units (SEC Form 4)
- Treace Medical Concepts Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
- Director Jain Deepti was granted 30,000 shares, increasing direct ownership by 43% to 100,243 units (SEC Form 4)
- Director Bakewell John K was granted 30,000 shares, increasing direct ownership by 17% to 204,056 units (SEC Form 4)